Eli Lilly and Company $LLY Holdings Increased by Swedbank AB

Swedbank AB increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 10.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 1,255,839 shares of the company’s stock after purchasing an additional 116,905 shares during the quarter. Eli Lilly and Company makes up 1.4% of Swedbank AB’s holdings, making the stock its 9th biggest position. Swedbank AB’s holdings in Eli Lilly and Company were worth $1,037,210,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the 1st quarter worth about $27,000. Citizens National Bank Trust Department grew its position in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new position in shares of Eli Lilly and Company during the 1st quarter worth $40,000. Finally, Mascagni Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter worth $43,000. Institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, Director Jamere Jackson bought 200 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $755.85 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $942.35. The company has a 50 day simple moving average of $741.52 and a two-hundred day simple moving average of $778.38. The stock has a market cap of $715.38 billion, a price-to-earnings ratio of 49.40, a PEG ratio of 1.05 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the business posted $3.92 EPS. The business’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company’s payout ratio is currently 39.22%.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 30th. UBS Group cut their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Erste Group Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. Finally, Leerink Partners restated a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $950.17.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.